# OnCo record azacitidine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/azacitidine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "azacitidine" ;
  schema:name "Azacitidine"@en ;
  schema:description "A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment."@en ;
  schema:url <https://onco.cc/drugs/azacitidine/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Azacitidine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q416451> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Azacitidine> ;
  onco:status "approved" ;
  onco:modality "Small-molecule hypomethylating agent (cytotoxic)" ;
  schema:alternateName "Vidaza / Onureg (oral)" ;
  onco:approval "US 2004: Myelodysplastic syndromes", "US 2020: Newly diagnosed AML unfit for intensive chemotherapy, with venetoclax (VIALE-A)", "US 2020: Oral azacitidine (Onureg) maintenance after intensive induction (QUAZAR AML-001)" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-older-unfit/>, <https://onco.cc/cancers/mds-higher-risk/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:trials <https://onco.cc/trials/viale-a/>, <https://onco.cc/trials/agile/>, <https://onco.cc/trials/nct04501120/>, <https://onco.cc/trials/nct04068597/>, <https://onco.cc/trials/nct04988555/>, <https://onco.cc/trials/nct04730258/>, <https://onco.cc/trials/nct05673057/>, <https://onco.cc/trials/nct07007312/>, <https://onco.cc/trials/nct04588922/>, <https://onco.cc/trials/nct02677922/>, <https://onco.cc/trials/nct05883956/>, <https://onco.cc/trials/nct04771130/>, <https://onco.cc/trials/nct04229979/>, <https://onco.cc/trials/nct04256317/>, <https://onco.cc/trials/nct07743112/>, <https://onco.cc/trials/nct04980885/>, <https://onco.cc/trials/nct06858618/>, <https://onco.cc/trials/nct05907057/>, <https://onco.cc/trials/nct04581512/>, <https://onco.cc/trials/nct05520567/>, <https://onco.cc/trials/nct07581002/>, <https://onco.cc/trials/nct04086264/>, <https://onco.cc/trials/nct04023526/>, <https://onco.cc/trials/nct07255872/>, <https://onco.cc/trials/nct06389292/>, <https://onco.cc/trials/nct06456463/>, <https://onco.cc/trials/nct05197426/>, <https://onco.cc/trials/nct07761533/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/> .